KPL-4 Cells

The KPL-4 cell line is a human breast cancer model originally derived from the malignant pleural effusion of a patient with inflammatory breast cancer. This cell line exhibits overexpression and amplification of HER2 (ErbB-2), as well as expression of other ErbB family receptors, including HER1 (EGFR) and HER3. Such characteristics make it particularly relevant for studying the molecular mechanisms underlying aggressive HER2-positive breast cancers and testing targeted therapies. KPL-4 cells are highly tumorigenic and have been used to establish xenograft models in immunodeficient mice. These models have demonstrated that KPL-4 tumors secrete significant amounts of interleukin-6 (IL-6), contributing to cachexia in host animals. The secretion of IL-6 correlates with tumor burden, highlighting the systemic effects of tumor biology in HER2-positive cancers. Importantly, KPL-4 cells respond to anti-HER2 therapies such as trastuzumab, although the in vivo efficacy of these treatments is variable, potentially due to the aggressive nature of this cancer model. The cell line has also been leveraged in advanced therapeutic research. For example, photoactivating antibody-mimetic drug conjugates (AMDCs) targeting HER2 have shown efficacy in KPL-4 xenograft models. These therapies combine HER2-specific binding molecules with cytotoxic payloads activated by light, achieving significant tumor reduction with minimal off-target effects. Such studies underscore the utility of KPL-4 cells in evaluating novel therapeutic modalities for HER2-positive breast cancer.